Cyclodextrin Complexes for the Treatment of Chagas Disease: A Literature Review
Abstract
:1. Introduction
2. Flowchart of This Study
Year | Reference | Title | Goals | Conclusions |
---|---|---|---|---|
2023 | [10] | New drug encapsulated incyclodextrin with promising anti-Trypanosoma cruzi activity. | Production and Characterization of a host–guest complex (Anti-Chagas Drug-Modified Chalcone (CHC) in 2-Hydroxypropyl-Beta-Cyclodextrin). | HPβCD/CHC showed promising activity against Trypanosoma cruzi. This complex offers improved water solubility and requires a lower amount of CHC to be effective. |
2023 | [11] | Elucidating the complexation of nifurtimox (NIF) with cyclodextrins. | Evaluate whether the formation of complexes with β-cyclodextrin and sulfobutyl ether-β-cyclodextrin would improve the solubility and dissolution rate of the drug. | β-CD/NIF and SBE-β-CD/NIF improved drug solubility and dissolution rate, showing significant stability in dissolution and crystallinity over 6 months at 25 °C and 40 °C. |
2023 | [12] | O-allyl-lawsone inclusion complex with 2-hydroxypropyl-β-cyclodextrin: Preparation, physical characterization, antiparasitic and antifunga activity. | Evaluate the antiparasitic and antifungal activity of O-allyl-lawsone (OAL) free and encapsulated in 2-hydroxypropyl-β-cyclodextrin (OAL MKN) against Trypanosoma cruzi. | HPβCD/OAL increased antiparasitic activity compared with the free form (OAL) while reducing cytotoxicity and enhancing selectivity for the trypomastigote form of T. cruzi. |
2021 | [13] | Characterization and trypanocidal activity of a drug carrier containing β-lapachone. | Investigate the in vitro action of anti-T. cruzi, effects of β-Lap encapsulated in 2-hydroxypropyl-β-cyclodextrin (2HP-β-CD), and its potential toxicity to mammalian cells. | The trypanocidal activity was increased by encapsulation of HP-β-CD/β-Lap compared with free naphthoquinone (β-Lap). |
2020 | [14] | Synthesis and biological evaluation of β-lapachone and nor-β-lapachone complexes with 2-hydroxypropyl-β-cyclodextrin as trypanocidal agents. | Study βLAP and its derivative complexes nor-β-Lapachone (NβL) with 2-hydroxypropyl-β-cyclodextrin to increase solubility and bioavailability. | HP-β-CD/βLAP and HP-β-CD/NβL increased the drug solubility and, additionally, vectorization was observed, resulting in higher biological activity against the epimastigote and trypomastigote forms of T. cruzi. |
2022 | [15] | Synthesis and study of the trypanocidal activity of catechol-containing 3-arylcoumarins, inclusion in β-cyclodextrin complexes and combination with benznidazole. | Evaluate trypanocidal activity and cytotoxicity of a series of catechol-containing 3-arylcoumarins, their combination with BZN, and inclusion in β-cyclodextrins (β-CDs). | Catechol-containing 3-arylcoumarins showed moderate trypanocidal activity against Trypanosoma cruzi, and their inclusion in β-cyclodextrins improved solubility. Combining these coumarins with benznidazole (BZN) further enhanced their effectiveness. |
2018 | [16] | Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. | Conduct a literature review to identify current pharmaceutical technologies used in conjunction with BNZ to improve therapy for Chagas disease. | Uma menor concentração de BNZ foi necessária para eliminar 50% das formas tripomastigotas de T. cruzi. Isso foi alcançado através da formação de complexos BNZ/CD e da modulação e vetorização do tratamento anti-Chagas utilizando estruturas metal-orgânicas. |
2017 | [17] | Benznidazole nanoformulates: A chance to improve therapeutics for Chagas disease. | Describe the characterization of several encapsulated formulations of benznidazole, currently a first-line medication for the treatment of Chagas disease. | The in vitro cytotoxicity of BZN/CDs was significantly lower than that of free benznidazole, while their trypanocidal activity was not impaired. |
2011 | [18] | Activity of a metronidazole analogue and its β-cyclodextrin complex against Trypanosoma cruzi. | Prepare an inclusion complex between a metronidazole iodide analog (MTZ-I) and cyclodextrin (CD) to develop a safer and more effective method of treating Trypanosoma cruzi infections. | MTZ-I and MTZ-I/β-CD were 10 times more active than MTZ, indicating that the presence of an iodine atom in the side chain increased trypanocidal activity while maintaining its cytotoxicity. |
2011 | [19] | Modulated dissolution rate of the antichagasic benznidazole inclusion complex and cyclodextrin using hydrophilic polymer. | Investigate the utility of hydroxypropylmethylcellulose (HPMC) polymer in controlling the release of BNZ from solid inclusion complexes with cyclodextrin to overcome the problem of its bioavailability. | The addition of HPMC to BZN/CD inclusion complexes significantly improved the dissolution rate and controlled drug release, showing promising potential for Chagas disease therapy. |
2012 | [20] | Benznidazole drug delivery by binary and multicomponent inclusion complexes using cyclodextrins and polymers. | Develop and characterize inclusion complexes in binary systems with BNZ and randomly methylated β-cyclodextrin (RMβCD), and in ternary systems with BNZ, RMβCD, and hydrophilic polymers. | Cyclodextrin-based inclusion complexes with benznidazole (BNZ) and hydrophilic polymers demonstrated effective, standardized, and safe drug delivery. |
2008 | [21] | Study of the interaction between hydroxymethyl nitrofurazone and 2-hydroxypropyl-β-cyclodextrin. | Characterize an NFOH inclusion complex in 2-hydroxypropyl-β-cyclodextrin (HP-β-CD). | HP-β-CD/NFOH significantly reduced the toxic effects of NFOH, according to preliminary toxicity studies and cell viability tests. |
2007 | [22] | Hydroxymethylnitrofurazone inclusion complex: dimethyl-β-cyclodextrin: a physicochemical characterization. | Characterize inclusion complexes formed between NFOH and dimethyl-β-cyclodextrin (DM-β-CD) through complexation/release kinetics and solubility isotherm experiments using ultraviolet (UV)–visible spectrophotometry and dynamics measurement. | NFOH/DM-β-CD showed improved solubility and favorable complexation, as demonstrated by solubility isotherm studies. |
3. Brief Review
3.1. Cyclodextrin
3.2. Industrial Applications
3.3. Complexation Mechanism
3.4. Chagas Disease
3.5. Biological Cycle
3.6. Nifurtimox and Benznidazole
3.7. Studies Conducted on the Treatment of T. cruzi
4. Impact of Cyclodextrins on the Optimization of Drug Solubility and Efficacy
5. Impact of Cyclodextrins with Benznidazole in the Treatment of Chagas Disease
6. Impact of Cyclodextrins with Natural Products in the Treatment of Chagas Disease
7. Discussion
8. Final Considerations
9. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Crini, G. Review: A History of Cyclodextrins. Chem. Rev. 2014, 114, 10940–10975. [Google Scholar] [CrossRef]
- Schijman, A.G.; Alonso-Padilla, J.; Britto, C.; Herrera Bernal, C.P. Retrospect, advances and challenges in Chagas disease diagnosis: A comprehensive review. Lancet Reg. Health Am. 2024, 36, 100821. [Google Scholar] [CrossRef] [PubMed]
- Pérez-Molina, J.A.; Molina, I. Chagas disease. Lancet 2018, 391, 82–94. [Google Scholar] [CrossRef] [PubMed]
- Goldenberg, S. Chagas disease treatment: A 120-year-old challenge to public health. Memórias Do Inst. Oswaldo Cruz 2022, 117, e210501chgsa. [Google Scholar] [CrossRef]
- Garibyan, A.; Terekhova, I. Complex formation with modified cyclodextrins for improving biopharmaceutical properties of baricitinib, a novel immunomodulatory drug. J. Mol. Liq. 2024, 406, 125016. [Google Scholar] [CrossRef]
- Paiva-Santos, A.C.; Ferreira, L.; Peixoto, D.; Silva, F.; Soares, M.J.; Zeinali, M.; Zafar, H.; Mascarenhas-Melo, F.; Raza, F.; Mazzola, P.G.; et al. Cyclodextrins as an encapsulation molecular strategy for volatile organic compounds—Pharmaceutical applications. Colloids Surf. B Biointerfaces 2022, 218, 112758. [Google Scholar] [CrossRef]
- Pandey, R.P.; Nascimento, M.S.; Moore, C.E.; Raj, V.S.; Kalil, J.; Cunha-Neto, E. New Approaches for the Treatment of Chagas Disease. Curr. Drug Targets 2021, 22, 835–841. [Google Scholar] [CrossRef] [PubMed]
- Sguassero, Y.; Cuesta, C.B.; Roberts, K.N.; Hicks, E.; Comandé, D.; Ciapponi, A.; Sosa-Estani, S. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies. PLoS ONE 2015, 10, e0139363. [Google Scholar] [CrossRef] [PubMed]
- Dias, L.C.; Dessoy, M.A.; Silva, J.J.N.; Thiemann, O.H.; Oliva, G.; Andricopulo, A.D. Quimioterapia da doença de Chagas: Estado da arte e perspectivas no desenvolvimento de novos fármacos. Química Nova 2009, 32, 2444–2457. [Google Scholar] [CrossRef]
- Zanetti, I.; do Nascimento Oliveira, L.; de Azevedo Maia, F.L.; de Santiago-Silva, K.M.; Pereira, P.M.L.; Albuquerque, M.G.; Gonçalves, R.S.B.; de Lima Ferreira Bispo, M.; Yamada-Ogatta, S.F.; Magalhães, A.; et al. Cyclodextrin-encapsulated new drug with promising anti-Trypanosoma cruzi activity. J. Therm. Anal. Calorim. 2023, 148, 10821–10834. [Google Scholar] [CrossRef]
- Bedogni, G.; Arrúa, E.; Seremeta, K.; Okulik, N.; Salomon, C. Elucidating the complexation of nifurtimox with cyclodextrins. J. Mol. Liq. 2023, 382, 121852. [Google Scholar] [CrossRef]
- Nicoletti, C.D.; dos Santos Galvão, R.M.; de Sá Haddad Queiroz, M.; Barboclher, L.; Faria, A.F.M.; Teixeira, G.P.; Souza, A.L.A.; de Carvalho da Silva, F.; Ferreira, V.F.; da Silva Lima, C.H.; et al. Inclusion complex of O-allyl-lawsone with 2-hydroxypropyl-β-cyclodextrin: Preparation, physical characterization, antiparasitic and antifungal activity. J. Bioenerg. Biomembr. 2023, 55, 233–248. [Google Scholar] [CrossRef] [PubMed]
- Barbosa, J.M.C.; Nicoletti, C.D.; da Silva, P.B.; Melo, T.G.; Futuro, D.O.; Ferreira, V.F.; Salomão, K. Characterization and trypanocidal activity of a β-lapachone-containing drug carrier. PLoS ONE 2021, 16, e0246811. [Google Scholar] [CrossRef] [PubMed]
- Nicoletti, C.D.; Faria, A.F.M.; de Sá Haddad Queiroz, M.; dos Santos Galvão, R.M.; Souza, A.L.A.; Futuro, D.O.; Faria, R.X.; Ferreira, V.F. Synthesis and biological evaluation of β-lapachone and nor-β-lapachone complexes with 2-hydroxypropyl-β-cyclodextrin as trypanocidal agents. J. Bioenerg. Biomembr. 2020, 52, 185–197. [Google Scholar] [CrossRef]
- Pozo-Martínez, J.; Salgado, F.; Liempi, A.; Kemmerling, U.; Mera-Adasme, R.; Olea-Azar, C.; Moncada-Basualto, M.; Borges, F.; Uriarte, E.; Matos, M.J. Synthesis and study of the trypanocidal activity of catechol-containing 3-arylcoumarins, inclusion in β-cyclodextrin complexes and combination with benznidazole. Arab. J. Chem. 2022, 15, 103641. [Google Scholar] [CrossRef]
- de Ferraz, L.R.M.; Alves, A.É.G.; da Nascimento, D.D.S.S.; Amariz, I.A.; Ferreira, A.S.; Costa, S.P.M.; Rolim, L.A.; Lima, Á.A.N.; Rolim Neto, P.J. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. Acta Trop. 2018, 185, 127–132. [Google Scholar] [CrossRef]
- Vinuesa, T.; Herráez, R.; Oliver, L.; Elizondo, E.; Acarregui, A.; Esquisabel, A.; Pedraz, J.L.; Ventosa, N.; Veciana, J.; Viñas, M. Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease. Am. J. Trop. Med. Hyg. 2017, 97, 1469–1476. [Google Scholar] [CrossRef]
- Lopes, M.S.; Sales Júnior, P.A.; Lopes, A.G.F.; Yoshida, M.I.; Silva, T.H.A.; Romanha, A.J.; Alves, R.J.; Oliveira, R.B. The activity of a metronidazole analogue and its β-cyclodextrin complex against. Trypanos. Cruzi. Memórias Do Inst. Oswaldo Cruz 2011, 106, 1055–1057. [Google Scholar] [CrossRef]
- Sá-Barreto, L.C.L.; Gustmann, P.C.; Garcia, F.S.; Maximiano, F.P.; Novack, K.M.; Cunha-Filho, M.S.S. Modulated dissolution rate from the inclusion complex of antichagasic benznidazole and cyclodextrin using hydrophilic polymer. Pharm. Dev. Technol. 2013, 18, 1035–1041. [Google Scholar] [CrossRef] [PubMed]
- Soares-Sobrinho, J.L.; Santos, F.L.A.; Lyra, M.A.M.; Alves, L.D.S.; Rolim, L.A.; Lima, A.A.N.; Nunes, L.C.C.; Soares, M.F.R.; Rolim-Neto, P.J.; Torres-Labandeira, J.J. Benznidazole drug delivery by binary and multicomponent inclusion complexes using cyclodextrins and polymers. Carbohydr. Polym. 2012, 89, 323–330. [Google Scholar] [CrossRef]
- Grillo, R.; Melo, N.F.S.; Moraes, C.M.; de Lima, R.; Menezes, C.M.S.; Ferreira, E.I.; Rosa, A.H.; Fraceto, L.F. Study of the interaction between hydroxymethylnitrofurazone and 2-hydroxypropyl-β-cyclodextrin. J. Pharm. Biomed. Anal. 2008, 47, 295–302. [Google Scholar] [CrossRef] [PubMed]
- Grillo, R.; Melo, N.F.S.; Fraceto, L.F.; Brito, C.L.; Trossini, G.H.G.; Menezes, C.M.S.; Ferreira, E.I.; Moraes, C.M. Physicochemical characterization of the inclusion complex between hydroxymethylnitrofurazone and hydroxypropyl-beta-cyclodextrin. Química Nova 2008, 31, 290–295. [Google Scholar] [CrossRef]
- Carneiro, S.; Costa Duarte, F.; Heimfarth, L.; Siqueira Quintans, J.; Quintans-Júnior, L.; Veiga Júnior, V.; Neves de Lima, Á. Cyclodextrin–Drug Inclusion Complexes: In Vivo and In Vitro Approaches. Int. J. Mol. Sci. 2019, 20, 642. [Google Scholar] [CrossRef]
- Santos, C.R. da S.; Silva, É.A. Cyclodextrins: Possible therapeutic agents in neurodegenerative diseases. Res. Soc. Dev. 2022, 11, e400111335610. [Google Scholar] [CrossRef]
- Davis, M.E.; Brewster, M.E. Cyclodextrin-based pharmaceutics: Past, present and future. Nat. Rev. Drug Discov. 2004, 3, 1023–1035. [Google Scholar] [CrossRef]
- Del Valle, E.M.M. Cyclodextrins and their uses: A review. Process Biochem. 2004, 39, 1033–1046. [Google Scholar] [CrossRef]
- Cid-Samamed, A.; Rakmai, J.; Mejuto, J.C.; Simal-Gandara, J.; Astray, G. Cyclodextrins inclusion complex: Preparation methods, analytical techniques and food industry applications. Food Chem. 2022, 384, 132467. [Google Scholar] [CrossRef] [PubMed]
- Fenyvesi, É.; Vikmon, M.; Szente, L. Cyclodextrins in Food Technology and Human Nutrition: Benefits and Limitations. Crit. Rev. Food Sci. Nutr. 2016, 56, 1981–2004. [Google Scholar] [CrossRef]
- Hu, Y.; Qiu, C.; Qin, Y.; Xu, X.; Fan, L.; Wang, J.; Jin, Z. Cyclodextrin–phytochemical inclusion complexes: Promising food materials with targeted nutrition and functionality. Trends Food Sci. Technol. 2021, 109, 398–412. [Google Scholar] [CrossRef]
- Yildiz, Z.I.; Celebioglu, A.; Kilic, M.E.; Durgun, E.; Uyar, T. Menthol/cyclodextrin inclusion complex nanofibers: Enhanced water-solubility and high-temperature stability of menthol. J. Food Eng. 2018, 224, 27–36. [Google Scholar] [CrossRef]
- Jansook, P.; Ogawa, N.; Loftsson, T. Cyclodextrins: Structure, physicochemical properties and pharmaceutical applications. Int. J. Pharm. 2018, 535, 272–284. [Google Scholar] [CrossRef] [PubMed]
- Lima, P.S.S.; Lucchese, A.M.; Araújo-Filho, H.G.; Menezes, P.P.; Araújo, A.A.S.; Quintans-Júnior, L.J.; Quintans, J.S.S. Inclusion of terpenes in cyclodextrins: Preparation, characterization and pharmacological approaches. Carbohydr. Polym. 2016, 151, 965–987. [Google Scholar] [CrossRef]
- Ryzhakov, A.; do Thi, T.; Stappaerts, J.; Bertoletti, L.; Kimpe, K.; Sá Couto, A.R.; Saokham, P.; van den Mooter, G.; Augustijns, P.; Somsen, G.W.; et al. Self-Assembly of Cyclodextrins and Their Complexes in Aqueous Solutions. J. Pharm. Sci. 2016, 105, 2556–2569. [Google Scholar] [CrossRef] [PubMed]
- Noël, S.; Léger, B.; Ponchel, A.; Sadjadi, S.; Monflier, E. Cyclodextrins as multitask agents for metal nano-heterogeneous catalysis: A review. Environ. Chem. Lett. 2021, 19, 4327–4348. [Google Scholar] [CrossRef]
- Tang, W.; Zou, C.; Da, C.; Cao, Y.; Peng, H. A review on the recent development of cyclodextrin-based materials used in oilfield applications. Carbohydr. Polym. 2020, 240, 116321. [Google Scholar] [CrossRef] [PubMed]
- Verma, M.; Lee, I.; Hong, Y.; Kumar, V.; Kim, H. Multifunctional β-Cyclodextrin-EDTA-Chitosan polymer adsorbent synthesis for simultaneous removal of heavy metals and organic dyes from wastewater. Environ. Pollut. 2022, 292, 118447. [Google Scholar] [CrossRef]
- Liu, Z.; Ye, L.; Xi, J.; Wang, J.; Feng, Z. Cyclodextrin polymers: Structure, synthesis, and use as drug carriers. Prog. Polym. Sci. 2021, 118, 101408. [Google Scholar] [CrossRef]
- Loftsson, T.; Duchene, D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 2007, 329, 1–11. [Google Scholar] [CrossRef]
- Szejtli, J. Introduction and General Overview of Cyclodextrin Chemistry. Chem. Rev. 1998, 98, 1743–1754. [Google Scholar] [CrossRef]
- Silva, R.M.; de Araújo, M.P.; Piauilino, C.A.; Rocha, M.S.; Silva, I.S.; da Silva, F.I.; Lima, F.C.A.; Almeida, F.R. de C.; Meneses, A.K.S.; de Sousa, S.A.A.; et al. Inclusion complex of 2-phenylethanol in β-cyclodextrin: Preparation, characterization, computational study and evaluation of antinociceptive activity. J. Mol. Struct. 2024, 1318, 139236. [Google Scholar] [CrossRef]
- Francis, S.M.; Xavier, E.N. Solubility Enhancement of Lawsone by Complexation with Beta Cyclodextrin. Indian J. Pharm. Educ. Res. 2022, 56, 706–715. [Google Scholar] [CrossRef]
- Manolikar, M.K.; Sawant, M.R. Study of solubility of isoproturon by its complexation with β-cyclodextrin. Chemosphere 2003, 51, 811–816. [Google Scholar] [CrossRef] [PubMed]
- Rudrangi, S.R.S.; Bhomia, R.; Trivedi, V.; Vine, G.J.; Mitchell, J.C.; Alexander, B.D.; Wicks, S.R. Influence of the preparation method on the physicochemical properties of indomethacin and methyl-β-cyclodextrin complexes. Int. J. Pharm. 2015, 479, 381–390. [Google Scholar] [CrossRef] [PubMed]
- Scalia, S.; Molinari, A.; Casolari, A.; Maldotti, A. Complexation of the sunscreen agent, phenylbenzimidazole sulphonic acid with cyclodextrins: Effect on stability and photo-induced free radical formation. Eur. J. Pharm. Sci. 2004, 22, 241–249. [Google Scholar] [CrossRef] [PubMed]
- Alghaith, A.F.; Mahrous, G.M.; Alenazi, A.S.; ALMufarrij, S.M.; Alhazzaa, M.S.; Radwan, A.A.; Alhamed, A.S.; bin Salamah, M.S.; Alshehri, S. Dissolution enhancement of Gefitinib by solid dispersion and complexation with β-cyclodextrins: In vitro testing, cytotoxic activity, and tablet formulation. Saudi Pharm. J. 2024, 32, 102070. [Google Scholar] [CrossRef]
- Jagdale, S.C.; Gawali, V.U.; Kuchekar, B.S.; Chabukswar, A.R. Formulation and in vitro evaluation of taste-masked oro-dispersible dosage form of diltiazem hydrochloride. Braz. J. Pharm. Sci. 2011, 47, 907–916. [Google Scholar] [CrossRef]
- Da Silva Pires, Y.M.; Almeida, L.R.; Araújo Meirelles, L.M. Tenoxicam dissolution profile in the beta-cyclodextrin inclusion complex. Rev. Eletrônica De Farmácia 2016, 13, 64. [Google Scholar] [CrossRef]
- Hassan, H.A.; Al-Marzouqi, A.H.; Jobe, B.; Hamza, A.A.; Ramadan, G.A. Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with β-cyclodextrin using supercritical carbon dioxide. J. Pharm. Biomed. Anal. 2007, 45, 243–250. [Google Scholar] [CrossRef]
- Klein, N.; Hurwitz, I.; Durvasula, R. Globalization of Chagas Disease: A Growing Concern in Nonendemic Countries. Epidemiol. Res. Int. 2012, 2012, 136793. [Google Scholar] [CrossRef]
- Echavarría, N.G.; Echeverría, L.E.; Stewart, M.; Gallego, C.; Saldarriaga, C. Chagas Disease: Chronic Chagas Cardiomyopathy. Curr. Probl. Cardiol. 2021, 46, 100507. [Google Scholar] [CrossRef] [PubMed]
- Gascon, J.; Bern, C.; Pinazo, M.-J. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 2010, 115, 22–27. [Google Scholar] [CrossRef] [PubMed]
- Posada, E.; Pell, C.; Angulo, N.; Pinazo, M.J.; Gimeno, F.; Elizalde, I.; Gysels, M.; Muñoz, J.; Pool, R.; Gascón, J. Bolivian migrants with Chagas disease in Barcelona, Spain: A qualitative study of dietary changes and digestive problems. Int. Health 2011, 3, 289–294. [Google Scholar] [CrossRef]
- Strasen, J.; Williams, T.; Ertl, G.; Zoller, T.; Stich, A.; Ritter, O. Epidemiology of Chagas disease in Europe: Many calculations, little knowledge. Clin. Res. Cardiol. 2014, 103, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Chagas, C. New human trypanozomiasis: Studies on the morphology and evolutionary cycle of Schizotrypanum cruzi n. gen., n. sp., etiological agent of a new morbid entity in man. Memórias Do Inst. Oswaldo Cruz 1909, 1, 159–218. [Google Scholar] [CrossRef]
- da Pita, S.S.R.; Pascutti, P.G. Therapeutic Targets in Chagas’ Disease: A Focus on Trypanothione Reductase. Rev. Virtual De Química 2011, 3, 307–324. [Google Scholar] [CrossRef]
- Costa, M.; Tavares, V.; Aquino, M.V.; Moreira, D. Chagas disease: A bibliographical review. Rev. Eletrônica Da Fac. De Ceres 2013, 2, 3. [Google Scholar] [CrossRef]
- Scariot, D.B.; Staneviciute, A.; Zhu, J.; Li, X.; Scott, E.A.; Engman, D.M. Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical diseases? Front. Cell. Infect. Microbiol. 2022, 12, 1000972. [Google Scholar] [CrossRef]
- Rassi, A., Jr.; Rassi, A.; Marin-Neto, J.A. Chagas disease. Lancet 2010, 375, 1388–1402. [Google Scholar] [CrossRef]
- de Oliveira, M.F.; Nagao-Dias, A.T.; de Oliveira Pontes, V.M.; Souza Júnior, A.S.; Luna Coelho, H.L.; Branco Coelho, I.C. Etiological treatment of Chagas disease in Brazil. Rev. De Patol. Trop. 2008, 37, 209–228. [Google Scholar] [CrossRef]
- Dias, J.C.P.; Coura, J.R. Chagas Disease Clinic and Therapy: A Practical Approach for the General Practitioner; Editora FIOCRUZ: Rio de Janeiro, Brazil, 1997. [Google Scholar] [CrossRef]
- Guedes, P.M.M.; Veloso, V.M.; Afonso, L.C.C.; Caliari, M.V.; Carneiro, C.M.; Diniz, L.F.; Marques-da-Silva, E.A.; Caldas, I.S.; do Valle Matta, M.A.; Souza, S.M.; et al. Development of chronic cardiomyopathy in canine Chagas disease correlates with high IFN-γ, TNF-α, and low IL-10 production during the acute infection phase. Vet. Immunol. Immunopathol. 2009, 130, 43–52. [Google Scholar] [CrossRef]
- Carlos Pinto Dias, J.; del Grande Cláudio, L.; Maia Lima, M.; Albajar-Viñas, P.; Albuquerque e Silva, R.; Vieira Alves, R.; Maia da Costa, V. Changes in the paradigm of clinical and therapeutic management of Chagas disease: Advances and perspectives in the search for comprehensive health. Epidemiol. E Serviços De Saúde 2016, 25, 1–10. [Google Scholar] [CrossRef]
- Esteso, M.A.; Romero, C.M. Cyclodextrins: Properties and Applications. Int. J. Mol. Sci. 2024, 25, 4547. [Google Scholar] [CrossRef] [PubMed]
- Rincón-López, J.; Almanza-Arjona, Y.C.; Riascos, A.P.; Rojas-Aguirre, Y. Technological evolution of cyclodextrins in the pharmaceutical field. J. Drug Deliv. Sci. Technol. 2021, 61, 102156. [Google Scholar] [CrossRef] [PubMed]
- Aiassa, V.; Garnero, C.; Zoppi, A.; Longhi, M.R. Cyclodextrins and Their Derivatives as Drug Stability Modifiers. Pharmaceuticals 2023, 16, 1074. [Google Scholar] [CrossRef]
- Venturini, C.d.G.; Nicolini, J.; Machado, C.; Machado, V.G. Properties and recent applications of cyclodextrins. Química Nova 2008, 31, 360–368. [Google Scholar] [CrossRef]
- Davies, C.; Cardozo, R.M.; Negrette, O.S.; Mora, M.C.; Chung, M.C.; Basombrío, M.A. Hydroxymethylnitrofurazone Is Active in a Murine Model of Chagas’ Disease. Antimicrob. Agents Chemother. 2010, 5, 3584–3589. [Google Scholar] [CrossRef]
- Ferreira, S.B.; Gonzaga, D.T.G.; Santos, W.C.; de Araújo, K.G.L.; Ferreira, V.F. ß-Lapachone: Medicinal chemistry significance and structural modifications. Rev. Virtual De Química 2010, 2, 140–160. [Google Scholar] [CrossRef]
- Dos Anjos, D.O.; Sobral Alves, E.S.; Gonçalves, V.T.; Fontes, S.S.; Nogueira, M.L.; Suarez-Fontes, A.M.; Neves da Costa, J.B.; Rios-Santos, F.; Vannier-Santos, M.A. Effects of a novel β-lapachone derivative on Trypanosoma cruzi: Parasite death involving apoptosis, autophagy, and necrosis. Int. J. Parasitol. Drugs Drug Resist. 2016, 6, 207–219. [Google Scholar] [CrossRef]
- Fraceto, L.F.; Gonçalves, M.M.; Moraes, C.M.; Araújo, D.R.; Zanella, L.; Paula, E.; Pertinhez, T.A. Characterization of the ropivacaine:beta-cyclodextrin inclusion complex. Química Nova 2007, 30, 1203–1207. [Google Scholar] [CrossRef]
- Kerdpol, K.; Kicuntod, J.; Wolschann, P.; Mori, S.; Rungnim, C.; Kunaseth, M.; Okumura, H.; Kungwan, N.; Rungrotmongkol, T. Cavity Closure of 2-Hydroxypropyl-β-Cyclodextrin: Replica Exchange Molecular Dynamics Simulations. Polymers 2019, 11, 145. [Google Scholar] [CrossRef]
- Ignaczak, A.; Orszański, Ł.; Adamiak, M.; Olejniczak, A. B Comparative DFT study of inclusion complexes of thymidine-carborane conjugate with β-cyclodextrin and heptakis(2,6-O-dimethyl)-β-cyclodextrin in water. J. Mol. Liq. 2020, 315, 113767. [Google Scholar] [CrossRef]
- Hancu, G.; Papp, L.A.; Tóth, G.; Kelemen, H. The Use of Dual Cyclodextrin Chiral Selector Systems in the Enantioseparation of Pharmaceuticals by Capillary Electrophoresis: An Overview. Molecules 2021, 26, 2261. [Google Scholar] [CrossRef] [PubMed]
- Monteiro, L.M.; Tavares, G.D.; Ferreira, E.I.; Consiglieri, V.O.; Bou-Chacra, N.A.; Löbenberg, R. Reverse phase high-performance liquid chromatography for quantification of hydroxymethylnitrofurazone in polymeric nanoparticles. Brazilian J. Pharm. Sci. 2015, 51, 561–567. [Google Scholar] [CrossRef]
- Sharma, P.; Singh, M. An ongoing journey of chalcone analogues as single and multi-target ligands in the field of Alzheimer’s disease: A review with structural aspects. Life Sci. 2023, 320, 121568. [Google Scholar] [CrossRef] [PubMed]
- Cruz, J.N.; Silva, L.B.; Sousa Filho, J.S.; Vale, J.K.L. Development of New Inhibitors of the Enzyme Dihydroorotate Dehydrogenase (DHODH) from Leishmania sp. Res. Soc. Dev. 2021, 10, e18101623087. [Google Scholar] [CrossRef]
- Gonçalves-Santos, E.; Caldas, I.S.; Fernandes, V.Â.; Franco, L.L.; Pelozo, M.F.; Feltrim, F.; Maciel, J.S.; Machado, J.V.C.; Gonçalves, R.V.; Novaes, R.D. Pharmacological potential of new metronidazole/eugenol/dihydroeugenol hybrids against Trypanosoma cruzi in vitro and in vivo. Int. Immunopharmacol. 2023, 121, 110416. [Google Scholar] [CrossRef]
- Gomes, C.L.; de Albuquerque Wanderley Sales, V.; Gomes de Melo, C.; Ferreira da Silva, R.M.; Vicente Nishimura, R.H.; Rolim, L.A.; Rolim Neto, P.J. Beta-lapachone: Natural occurrence, physicochemical properties, biological activities, toxicity and synthesis. Phytochemistry 2021, 186, 112713. [Google Scholar] [CrossRef]
- Foulkes, M.J.; Tolliday, F.H.; Henry, K.M.; Renshaw, S.A.; Jones, S. Evaluation of the anti-inflammatory effects of synthesised tanshinone I and isotanshinone I analogues in zebrafish. PLoS ONE 2020, 15, e0240231. [Google Scholar] [CrossRef]
- Freitas, C.A.B.; Araújo, R.C.S.; Paz, S.P.A.; Silva, J.R.A.; Alves, C.N.; Lameira, J. Obtaining and Characterizing B-Cyclodextrin and Eugenol Inclusion Complex/Preparation and Characterization of Eugenol B-Cyclodextrin Inclusion Complex. Braz. J. Dev. 2021, 7, 33056–33070. [Google Scholar] [CrossRef]
- Nagoor Meeran, M.F.; Javed, H.; al Taee, H.; Azimullah, S.; Ojha, S.K. Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development. Front. Pharmacol. 2017, 8, 380. [Google Scholar] [CrossRef]
- Zhang, Y.; Tan, Y.; OuYang, Q.; Duan, B.; Wang, Z.; Meng, K.; Tan, X.; Tao, N. γ-Cyclodextrin encapsulated thymol for citrus preservation and its possible mechanism against Penicillium digitatum. Pestic. Biochem. Physiol. 2023, 194, 105501. [Google Scholar] [CrossRef] [PubMed]
- Serna-Escolano, V.; Serrano, M.; Valero, D.; Isabel Rodríguez-López, M.; Gabaldón, J.A.; Castillo, S.; Valverde, J.M.; Zapata, P.J.; Guillén, F.; Martínez-Romero, D. Thymol Encapsulated into HP-β-Cyclodextrin as an Alternative to Synthetic Fungicides to Induce Lemon Resistance against Sour Rot Decay. Molecules 2020, 25, 4348. [Google Scholar] [CrossRef]
- Franco, C.F.J.; Jordão, A.K.; Ferreira, V.F.; Pinto, A.C.; Souza, M.C.B.V.; Resende, J.A.L.C.; Cunha, A.C. Synthesis of new 2-aminocarbohydrate-1,4-naphthoquinone derivatives promoted by ultrasonic irradiation. J. Braz. Chem. Soc. 2011, 22, 187–193. [Google Scholar] [CrossRef]
- Dantas, E.; de Souza, F.; Nogueira, W.; Silva, C.; de Azevedo, P.; Soares Aragão, C.; Almeida, P.; Cardoso, M.; da Silva, F.; de Azevedo, E.; et al. Characterization and Trypanocidal Activity of a Novel Pyranaphthoquinone. Molecules 2017, 22, 1631. [Google Scholar] [CrossRef] [PubMed]
- da Oliveira, V.S.; Silva, C.C.; de Freitas Oliveira, J.W.; da Silva, M.S.; Ferreira, P.G.; da Siva, F.C.; Ferreira, V.F.; Barbosa, E.G.; Barbosa, C.G.; Moraes, C.B.; et al. The evaluation of in vitro antichagasic and anti-SARS-CoV-2 potential of inclusion complexes of β- and methyl-β-cyclodextrin with naphthoquinone. J. Drug Deliv. Sci. Technol. 2023, 81, 104229. [Google Scholar] [CrossRef]
- Chen, Q.; McGillivray, D.; Wen, J.; Zhong, F.; Quek, S.Y. Co-encapsulation of fish oil with phytosterol esters and limonene by milk proteins. J. Food Eng. 2013, 117, 505–512. [Google Scholar] [CrossRef]
- Răileanu, M.; Todan, L.; Voicescu, M.; Ciuculescu, C.; Maganu, M. A way for improving the stability of the essential oils in an environmental friendly formulation. Mater. Sci. Eng. C 2013, 33, 3281–3288. [Google Scholar] [CrossRef] [PubMed]
- Moghimi, R.; Ghaderi, L.; Rafati, H.; Aliahmadi, A.; McClements, D.J. Superior antibacterial activity of nanoemulsion of Thymus daenensis essential oil against E. coli. Food Chem. 2016, 194, 410–415. [Google Scholar] [CrossRef]
- Tobouti, P.L.; de Andrade Martins, T.C.; Pereira, T.J.; Mussi, M.C.M. Antimicrobial activity of copaiba oil: A review and a call for further research. Biomed. Pharmacother. 2017, 94, 93–99. [Google Scholar] [CrossRef]
- Ziech, R.E.; Farias, L.D.; Balzan, C.; Ziech, M.F.; Heinzmann, B.M.; Lameira, O.A.; Vargas, A.C. Antimicrobial activity of copaiba oleoresin (Copaifera reticulata) against coagulase-positive Staphylococcus isolated from cases of otitis in dogs. Pesqui. Veterinária Bras. 2013, 33, 909–913. [Google Scholar] [CrossRef]
- Menezes, A.C.S.; Alves, L.D.B.; Goldemberg, D.C.; de Melo, A.C.; Antunes, H.S. Anti-inflammatory and wound healing effect of Copaiba oleoresin on the oral cavity: A systematic review. Heliyon 2022, 8, e08993. [Google Scholar] [CrossRef]
- Carvalho, J.C.T.; Cascon, V.; Possebon, L.S.; Morimoto, M.S.S.; Cardoso, L.G.V.; Kaplan, M.A.C.; Gilbert, B. Topical antiinflammatory and analgesic activities of Copaifera duckei dwyer. Phytother. Res. 2005, 19, 946–950. [Google Scholar] [CrossRef]
- Lima, S.R.M.; Junior, V.F.V.; Christo, H.B.; Pinto, A.C.; Fernandes, P.D. In vivo and in vitro studies on the anticancer activity of Copaifera multijuga hayne and its fractions. Phytother. Res. 2003, 17, 1048–1053. [Google Scholar] [CrossRef] [PubMed]
- Pinheiro, J.; Tavares, E.; Silva, S.; Félix Silva, J.; Carvalho, Y.; Ferreira, M.; Araújo, A.; Barbosa, E.; Fernandes Pedrosa, M.; Soares, L.; et al. Inclusion Complexes of Copaiba (Copaifera multijuga Hayne) Oleoresin and Cyclodextrins: Physicochemical Characterization and Anti-Inflammatory Activity. Int. J. Mol. Sci. 2017, 18, 2388. [Google Scholar] [CrossRef]
- Kian, D.; Lancheros, C.A.C.; Assolini, J.P.; Arakawa, N.S.; Veiga-Júnior, V.F.; Nakamura, C.V.; Pinge-Filho, P.; Conchon-Costa, I.; Pavanelli, W.R.; Yamada-Ogatta, S.F.; et al. Trypanocidal activity of copaiba oil and kaurenoic acid does not depend on macrophage killing machinery. Biomed. Pharmacother. 2018, 103, 1294–1301. [Google Scholar] [CrossRef] [PubMed]
- Lou, J.; Teng, Z.; Zhang, L.; Yang, J.; Ma, L.; Wang, F.; Tian, X.; An, R.; Yang, M.; Zhang, Q.; et al. β-Caryophyllene/Hydroxypropyl-β-Cyclodextrin Inclusion Complex Improves Cognitive Deficits in Rats with Vascular Dementia through the Cannabinoid Receptor Type 2 -Mediated Pathway. Front. Pharmacol. 2017, 8, 2. [Google Scholar] [CrossRef]
- Kurkov, S.V.; Loftsson, T. Cyclodextrins. Int. J. Pharm. 2013, 453, 167–180. [Google Scholar] [CrossRef] [PubMed]
- Yao, Y.; Xie, Y.; Hong, C.; Li, G.; Shen, H.; Ji, G. Development of a myricetin/hydroxypropyl-β-cyclodextrin inclusion complex: Preparation, characterization, and evaluation. Carbohydr. Polym. 2014, 110, 329–337. [Google Scholar] [CrossRef]
- Silva, F.L.O.; Marques, M.B.F.; Yoshida, M.I.; Mussel, W.N.; Silveira, J.V.W.; Barroso, P.R.; Kato, K.C.; Martins, H.R.; Carneiro, G. Encapsulation of benznidazole in nanostructured lipid carriers and increased trypanocidal activity in a resistant Trypanosoma cruzi strain. Braz. J. Pharm. Sci. 2023, 59, e22111. [Google Scholar] [CrossRef]
- Gomes, D.C.; Medeiros, T.S.; Alves Pereira, E.L.; da Silva, J.F.O.; de Freitas Oliveira, J.W.; Fernandes-Pedrosa, M.F.; de Sousa da Silva, M.; da Silva-Júnior, A.A. From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease. Int. J. Mol. Sci. 2023, 24, 13778. [Google Scholar] [CrossRef]
- Morilla, M.J.; Ghosal, K.; Romero, E.L. Nanomedicines against Chagas disease: A critical review. Beilstein J. Nanotechnol. 2024, 15, 333–349. [Google Scholar] [CrossRef] [PubMed]
- Gonzaga, B.M.S.; Nisimura, L.M.; Coelho, L.L.; Ferreira, R.R.; Horita, S.I.M.; Beghini, D.G.; Estato, V.; Araújo-Jorge, T.C.; Garzoni, L.R. Unveiling Lovastatin’s Anti-Inflammatory Potential in Mouse’s Brain during Acute Trypanosoma cruzi Infection. Biology 2024, 13, 301. [Google Scholar] [CrossRef] [PubMed]
- Narwal, S.; Dhanda, T.; Sharma, P.; Sharma, V.; Dhankhar, S.; Garg, N.; Ghosh, N.S.; Rani, N. Current Therapeutic Strategies for Chagas Disease. Anti-Infect. Agents 2024, 22, 20–30. [Google Scholar] [CrossRef]
- García-Huertas, P.; Cardona-Castro, N. Advances in the treatment of Chagas disease: Promising new drugs, plants and targets. Biomed. Pharmacother. 2021, 142, 112020. [Google Scholar] [CrossRef]
Cyclodextrin | Glucose Unit Number | Molecular Weight | Cavity Diameter (Å) | Cavity Volume (Å3) | Aqueous Solubility at 25° C (% m/v) |
---|---|---|---|---|---|
α-CD | 6 | 972 | 4.5–5.3 | 174 | 14.5 |
β-CD | 7 | 1135 | 6.0–6.5 | 262 | 1.85 |
γ-CD | 8 | 1297 | 7.5–8.3 | 427 | 23.2 |
Symptom/Sign | Benznidazol | Nifurtimox |
---|---|---|
Anorexia | ++ | +++ |
Headache | + | ++ |
Dermatopathy | +++ | + |
Psychic excitement | - | +++ |
Gastralgia | + | +++ |
Insomnia | + | ++ |
Nausea | ++ | +++ |
Weight loss | + | +++ |
Polyneuropathy | + | +++ |
Vomiting | ++ | +++ |
Type of Cyclodextrin | Reference | Cyclodextrin Structure |
---|---|---|
β-cyclodextrin (β-CD) | [70] | |
2-Hydroxypropyl-β-cyclodextrin (HP-β-CD) | [71] | |
Dimethyl-β-cyclodextrin (DM-β-CD) | [72] | |
Ether sulfobutílico-β-cyclodextrin (SBE-β-CD) | [73] |
Molecule Name | Reference | Molecular Structure |
---|---|---|
HidroximetilNitrofurazone (NFOH) | [74] | |
Chalcones (CHC) | [75] | |
O-allyl-lawsone (OAL) | [12] | |
Nifurtimox (NF) | [76] | |
Benznidazole (BNZ) | [76] | |
Metronidazole (MTZ) | [77] | |
β-lapachone (β-Lap) | [78] | |
Nor-β-lapachone (NβL) | [79] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Taio, F.; Converti, A.; Lima, Á.A.N.d. Cyclodextrin Complexes for the Treatment of Chagas Disease: A Literature Review. Int. J. Mol. Sci. 2024, 25, 9511. https://doi.org/10.3390/ijms25179511
Taio F, Converti A, Lima ÁANd. Cyclodextrin Complexes for the Treatment of Chagas Disease: A Literature Review. International Journal of Molecular Sciences. 2024; 25(17):9511. https://doi.org/10.3390/ijms25179511
Chicago/Turabian StyleTaio, Fabrice, Attilio Converti, and Ádley Antonini Neves de Lima. 2024. "Cyclodextrin Complexes for the Treatment of Chagas Disease: A Literature Review" International Journal of Molecular Sciences 25, no. 17: 9511. https://doi.org/10.3390/ijms25179511